Canada markets closed

Rapid Dose Therapeutics Corp. (DOSE.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.21000.0000 (0.00%)
At close: 10:16AM EDT
Full screen
Previous Close0.2100
Open0.2100
Bid0.2000 x 0
Ask0.2250 x 0
Day's Range0.2100 - 0.2100
52 Week Range0.1700 - 0.5500
Volume7,645
Avg. Volume132,118
Market Cap16.184M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateOct. 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Rapid Dose Therapeutics Signs Exclusive Manufacturing and Distribution Agreement With MapleX Naturals Inc.
    GlobeNewswire

    Rapid Dose Therapeutics Signs Exclusive Manufacturing and Distribution Agreement With MapleX Naturals Inc.

    BURLINGTON, Ontario, April 13, 2021 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is a Canadian Life Science company focused on innovative drug and active ingredient delivery solutions. The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film, infused with an active ingredient (nutraceuticals, cannabis or pharmaceuticals) that is delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient. The Company is announcing today that it has entered into an exclusive manufacturing and distribution agreement with MapleX Naturals Inc. (“MapleX”) for its personal care product line of topical creams and lotions which are infused with natural ingredients such as Hemp and Canadian maple syrup, for sale by the Company to retailers across North America. MapleX was a founding shareholder in Consolidated Craft Brands (“CCB”) which was recently acquired by and amalgamated into a wholly-owned subsidiary of RDT. MapleX has significant experience “infusing Hemp” extracts (rich in Omega 3,6, and 9), into high end personal care products to provide a “humectant” which repairs the skin, locks in moisture, regulates oil production, reduces inflammation, and visibly smooths the skin. MapleX products are currently distributed in specialty retail locations across Canada. Dave Thompson, CEO of MapleX, commented, “We are excited to enter into this agreement with RDT. As a result, we look forward to providing customers in Canada and later in the United States with our MapleX product line. This agreement with RDT further allows us to introduce a range of beauty and cosmetic products to consumers. We are confident this will be a successful partnership and we look forward to achieving our growth objectives.” Mark Upsdell, CEO of RDT commented, “The agreement with MapleX is key to our product line expansion as we continue to grow our health and wellness portfolio of products to augment the opportunities from our ‘QuickStrip™ technology. The MapleX personal care line will offer an expanding range of Hemp infused topical creams, lotions and balms for private label clients looking to establish a retail brand in the non-regulated Hemp market through traditional retailers. Through the amalgamation with CCB, we have accelerated our entry into the Consumer Packaged Goods (CPG) segment of the market which provides RDT with multiple revenue streams and expanded product offerings. The health and wellness space is a logical progression in RDT’s journey to provide innovative transdermal and sublingual delivery technologies for therapeutic, cosmetic and enhanced recreational customer experiences. We have already shipped our first topical products and look forward to seeing them in retailers across Canada in the coming weeks.” About RDT Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to continually create innovative solutions for humans, animals, and plants. For more information, visit: www.rapiddose.ca For inquiries please contact: Mark UpsdellPat McCarthy CEOManaging Director Capital Markets mupsdell@rapid-dose.compmccarthy@leedejonesgable.com Ofc (416) 477-1052Ofc (416) 365-8012

  • Rapid Dose Therapeutics Announces Grant of Incentive Stock Options and the Issuance of Warrants
    GlobeNewswire

    Rapid Dose Therapeutics Announces Grant of Incentive Stock Options and the Issuance of Warrants

    BURLINGTON, Ontario, March 30, 2021 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), announces, pursuant to its Stock Option Plan, the granting of incentive stock options to purchase 4,490,000 common shares at an exercise price of $0.24 per share. Each has a term of 2 years and vests equally every six months over the term. The grant of options is subject to the policies, and acceptance by, the Canadian Securities Exchange. In addition, the Company announces, pursuant to an advisory agreement, the issuance of 200,000 Share Purchase Warrants having an Exercise Price of $0.24 per share for a two year term ending March 28, 2023. Further, the Company announces, pursuant to an investment and public relations services agreement, the issuance of 200,000 Share Purchase Warrants having an Exercise Price of $0.24 per share for a two year term ending March 28, 2023. About RDT Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to continually create innovative solutions for humans, animals, and plants. For more information, visit: www.rapiddose.ca For inquiries please contact: Mark UpsdellPat McCarthy CEOManaging Director Capital Markets mupsdell@rapid-dose.compmccarthy@leedejonesgable.com Ofc (416) 477-1052Ofc (416) 365-8012

  • Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands
    GlobeNewswire

    Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands

    BURLINGTON, Ontario, March 19, 2021 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is a Canadian life sciences company focused on innovative drug and active ingredient delivery solutions. The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film infused with an active ingredient (nutraceuticals, cannabis or pharmaceuticals) that is delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient. The Company is announcing today that, further to its press release of March 8, 2021, it has closed the purchase and subsequent amalgamation of 2544737 Ontario Limited, operating as Consolidated Craft Brands (“CCB”), in a share transaction totalling $5,000,000 CDN. (Five million dollars Canadian). The transaction is an acquisition by RDT of CCB with CCB being amalgamated into a newly created subsidiary of RDT. 20,000,000 Units consisting of 1 common share and 1 common share purchase warrant have been issued subject to an eleven month escrow arrangement. Each common share has a deemed value of $0.25 per share while each warrant entitles the holder to acquire one common share of the Company at a price of $0.375 per common share for a two year period from the issuance date. In exchange, CCB becomes a wholly owned subsidiary of RDT. CCB brings CPG and Pharma manufacturing expertise, a Health Canada R&D License with developed proprietary formulations, branded products, several patent pending technologies for rapid onset beverage enhancements and a consortium of strategic alliances including First Nation majority shareholders. The balance sheet of CCB includes $3,000,000 in cash and cash equivalents including a repayable advance of $600,000 to RDT as an advance to closing of the transaction, equipment, inventory, patent pending technologies and the R&D License. In addition, liabilities in CCB are less than $50,000. The cash is now available to RDT to fund the ramp up of production to meet demand as it enters the Commercialization and Rapid Growth Phase in its development. About RDT Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT also provides a turn-key Managed Strip Service Program enabling RDT’s QuickStrip™ proprietary cannabis delivery technology to be licensed to select operators in identified markets. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals, and plants. For more information, visit: www.rapiddose.ca For inquiries please contact: Mark UpsdellPat McCarthy CEOManaging Director Capital Markets mupsdell@rapid-dose.com pmccarthy@leedejonesgable.com Ofc (416) 477-1052Ofc (416) 365-8012